<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124588</url>
  </required_header>
  <id_info>
    <org_study_id>NEXTBIO-632-EWD3</org_study_id>
    <nct_id>NCT04124588</nct_id>
  </id_info>
  <brief_title>Effectiveness of 'Nexpowder' for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal Bleeding</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Trial to Evaluate Safety and Effectiveness of Endoscopic Hemostactic Powder, 'Nexpowder' for Hemostatic Treatments of Nonvariceal, Upper Gastrointestinal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Next Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Next Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, randomized controlled trial to evaluate safety and effectiveness&#xD;
      of endoscopic hemostatic powder, 'Nexpowder' for hemostatic treatments of nonvariceal upper&#xD;
      gastrointestinal bleeding.&#xD;
&#xD;
      This study is a prospective, multi-center, single blind (for patients), controlled&#xD;
      investigation planned to evaluate safety and effectiveness of Nexpowder with 352 subject&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigational study is designed to compare effectiveness of using the standard-of-care&#xD;
      hemostatic therapy only, versus the standard-of-care hemostatic therapy plus an additional&#xD;
      hemostatic treatment using Nexpower for patients with nonvariceal, upper gastrointestinal&#xD;
      bleeding from ulcers with high-risk stigmata (Forrest classification Ia, Ib, or IIa).&#xD;
&#xD;
      The primary end-points will be evaluated by assessing the rates of re-bleeding, which occur&#xD;
      over three (3) days following initial hemostasis achieved with the standard-of-care&#xD;
      hemostatic therapy.&#xD;
&#xD;
      Secondary end-points consist of evaluating three items: 1) Ease of use of Nexpowder applied&#xD;
      for the test group after reaching initial hemostasis, 2) Nexpowder device malfunction and 3)&#xD;
      safety follow-up to check occurrence of adverse event(s)/re-bleeding at 30-day (+5) time&#xD;
      point.&#xD;
&#xD;
      Only the subjects whose initial hemostasis has been achieved will be registered for this&#xD;
      investigation but those who initial hemostasis has failed to be reached with the&#xD;
      standard-of-care therapie(s) shall not be registered for this investigation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rates of re-bleeding</measure>
    <time_frame>3 days</time_frame>
    <description>Assessing the rates of re-bleeding, which occur over three (3) days following initial hemostasis achieved with the standard-of-care hemostatic therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Adverse Events &amp; Long term Re-bleeding</measure>
    <time_frame>30 days (+5)</time_frame>
    <description>Safety follow-up to check occurrence of adverse event(s)/re-bleeding.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Nonvariceal Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;After&quot; achieving initial hemostasis only with the standard-of-care, endoscopic hemostatic therapie(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control gruop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;After&quot; achieving initial hemostasis only with the standard-of-care, Wrap up the first endoscopy without adding an additional procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nexpowder (Hemostatic powder)</intervention_name>
    <description>Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional Technique</intervention_name>
    <description>Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).</description>
    <arm_group_label>Control gruop</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female with age of older than 19 years.&#xD;
&#xD;
          -  Patients showing non-variceal upper GI bleeding symptoms&#xD;
&#xD;
          -  An endoscopic examination indicates that the patients's ulcer is categorized Class Ia,&#xD;
             Ib, or IIa according to the Forrest Classifications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eunhye Lee, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>NEXTBIOMEDICAL CO., LTD.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eunhye Lee, Ph.D</last_name>
    <phone>82-32-880-0820</phone>
    <email>ehlee@nextbiomedical.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Hee Maeng, MS</last_name>
    <phone>82-32-880-0860</phone>
    <email>jhmaeng@nextbiomedical.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soon Chun Hyang University Bucheon Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Gachon Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-Oh Kim, MD, Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Kyung-Oh Kim, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung-Gil Kim, MD Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

